Embolism News and Research

RSS

New guideline recommends against routine use of bed rest in pregnancy

In a new guideline, the Society for Maternal-Fetal Medicine has recommended against the routine use of bed rest in pregnancy.

3 Sep 2014

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.

2 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

ESC launches first recommendations on use of all new oral anticoagulants in pulmonary embolism

The first recommendations on the use of all new oral anticoagulants in pulmonary embolism are published today in new ESC Guidelines.

30 Aug 2014

Implantating DBS devices poses no greater risk of complications to older Parkinson's patients

Implantating deep brain stimulation devices poses no greater risk of complications to older patients than it does to younger patients with Parkinson's disease, researchers at Duke Medicine report.

26 Aug 2014

Delay in correcting abnormal cardiac rhythm linked with greater risk of thromboembolic complications

A delay of 12 hours or longer to correct an abnormal cardiac rhythm from atrial fibrillation was associated with a greater risk of thromboembolic complications such as stroke, according to a study in the August 13 issue of JAMA.

13 Aug 2014

Cardiovascular Research Foundation to co-sponsor 2014 VEINS conference

VEINS is an established Venous Endovascular Interventional Strategies group comprised of experts in the field whose primary aim is to provide a "How To" meeting for cardiologists and other healthcare providers who are interested in advancing their knowledge and skills in venous interventions and whose ultimate goal is developing their own comprehensive venous interventional program.

25 Jul 2014

Study aims at best way to treat deep vein thrombosis

Patients who have a clot in their legs and are considering whether to be treated with traditional blood-thinning medication or undergo a minimally-invasive catheter-based clot removal procedure should feel comfortable that there is no difference in death rates between the two treatments, although there are more bleeding risks with the catheter procedure, according to a study by Temple University School of Medicine researchers.

22 Jul 2014

Anti-clotting treatment not needed for all kids who undergo spine operations

Blood clots occur so rarely in children undergoing spine operations that most patients require nothing more than vigilant monitoring after surgery and should be spared risky and costly anti-clotting medications, according to a new Johns Hopkins Children's Center study.

16 Jul 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

Patient registry to help clinicians identify, manage people who have progressive lung disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

5 Jun 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Urine test can indicate presence of venous thromboembolism in patients at risks for clots

A new study by researchers from California and Canada indicates a simple urine test can indicate the presence of venous thromboembolism, a blood clot that has broken free from its point of origin and which travels through the bloodstream, eventually lodging in a vein.

19 May 2014

Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue

Among the drugs used for acute ischemic stroke, recombinant tissue plasminogen activator is widely accepted internationally. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke.

13 May 2014

New United Nations data show sharp decline in maternal deaths

New United Nations data show a 45% reduction in maternal deaths since 1990. An estimated 289 000 women died in 2013 due to complications in pregnancy and childbirth, down from 523 000 in 1990.

6 May 2014

Concise analysis of global disposable gloves market

MRRBIZ includes new market research report "Disposable Gloves Market For Medical and Non-Medical (Food, Cleanroom, Industrial And Other) Applications - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its large collection of research report.

6 May 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Managing pregnancy-related complications: an interview with Dr. Mark Zakowski

Pregnancy-related mortality has increased over the last 25 years. Ten years ago the top three pregnancy-related mortality diagnoses were hemorrhage, preeclampsia, and embolism (includes thrombotic and amniotic).

2 Apr 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014